Page URL: https://www.bionews.org.uk/page_96370

Stem cell vaccine works against multiple cancers in mice

19 February 2018
Appeared in BioNews 938

Researchers successfully used inactivated induced pluripotent stem cells (iPSCs) to elicit an immune response against different cancers in mice.

The team at Stanford University confirmed that iPSCs from mice and humans have similar expression levels of antigens to those found in different cancers.

Previous cancer vaccines have had limited success because only one antigen has generally been targeted, results have initially been promising but then resistance develops as cancer cells without the target antigen proliferate. The idea that stem cells and cancer cells have similar antigen profiles is not new and has the advantage that several known and unknown antigens can be presented to the immune system at the same time, allowing for a more effective immune response.

Studies have established that embryonic stem cells can protect mice from transplanted tumour but using inactivated iPSCs as an immunotherapy against cancer has the advantage that while embryonic stem cell rely on the availability of embryonic tissue and therefore have ethical and feasibility issues, iPSCs can be derived from adult cells.

'What surprised us most was the effectiveness of the iPSC vaccine in re-activating the immune system to target cancer,' said Dr Joseph Wu, lead author of the study. 'This approach may have clinical potential to prevent tumour recurrence or target distant metastases.'

The group used iPSCs created from mouse fibroblasts, in addition to an immune-boosting bacterial DNA fragment, to vaccinate mice before transplanting them with either breast, skin or lung cancer. While the control animals developed considerable tumours, the treated mice presented with smaller tumours or with tumour regression. These results highlight a potential prophylactic application of the vaccine, for example in the elderly or other groups who are prone to the development of cancers.

To confirm that the immune response is specific to cancer, the researchers transferred T cells from vaccinated animals into non-vaccinated animals with breast cancer and found that the tumours in the non-vaccinated animals also showed signs of regression. This approach did not work in mice with skin cancer, however, it was found to prevent regrowth of skin tumours after partial surgery, indicating a possible usefulness in real life skin cancer scenarios.

While the scientists note that there were no signs of an autoimmune reaction or other serious adverse effects, they caution that this therapeutic approach is far from being proven in humans. Professor Daniel Davis, Professor of Immunology at the University of Manchester, who was not involved in the study, added: 'As the authors say themselves, we have no idea if something like this could work in humans. If it does, this type of cancer treatment is most likely to be useful in combination with other therapies. In the meantime, as scientists often quip, this is good news for mice.'

SOURCES & REFERENCES
Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo
Elsevier |  15 February 2018
Stem cell vaccine immunizes lab mice against multiple cancers
EurekAlert |  15 February 2018
Stem cell vaccine protects mice from cancer
The Scientist |  15 February 2018
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
26 March 2018 - by Dr Greg Ball 
A ground-breaking new stem cell therapy has restored sight in the first two patients to receive it...
5 March 2018 - by Anna Mallach 
Bacteria commonly found on skin could be used as a treatment against skin cancer, researchers at the University of California, San Diego, have found...
10 July 2017 - by Meetal Solanki 
A revolutionary vaccine uses the patient’s own immune response to target tumour cells and could be the first step in bespoke, precision medicine. 
13 April 2015 - by Dr Nicoletta Charolidi 
A new type of cancer vaccine that enriches the immune system with tailor-made anti-tumour antibodies has shown early signs of promise...
2 July 2012 - by Dr Linda Wijlaars 
A gene that codes for nicotine antibodies has been successful in immunising mice against the drug's effects. But although the treatment appears to work in mice, any 'smoking vaccine' is still a long way off...
12 October 2009 - by Dr Will Fletcher 
Stem cells could potentially be used to vaccinate people against colon cancer. This surprising conclusion was made by researchers from China and the US after laboratory mice immunised with human embryonic stem (ES) cells experienced a dramatic decline in tumour growth compared to control mice. The idea that embryonic material may generate an anti-tumour response is an old one, but one that has never been tested outside animal research, so to find such an effect wit...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.